Ultragenyx Pharmaceutical (RARE) Income towards Parent Company (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Income towards Parent Company for 14 consecutive years, with -$185.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 22.52% year-over-year to -$185.0 million; the TTM figure through Mar 2026 stood at -$602.9 million (down 10.56% YoY), while the FY2025 annual figure was -$569.0 million, down 0.71% from the prior year.
• Income towards Parent Company fell to -$185.0 million in Q1 2026 per RARE's latest filing, from -$122.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$115.0 million in Q2 2025 and bottomed at -$245.1 million in Q3 2022.
• Historically, Income towards Parent Company has averaged -$155.0 million across 5 years, with a median of -$153.5 million in 2022.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 235.77% — and 2023, when it jumped 34.87%.
• Ultragenyx Pharmaceutical's Income towards Parent Company stood at -$153.5 million in 2022, then advanced by 19.5% to -$123.6 million in 2023, then decreased by 4.57% to -$129.2 million in 2024, then rose by 5.14% to -$122.6 million in 2025, then slumped by 50.95% to -$185.0 million in 2026.
• Business Quant data shows RARE's Income towards Parent Company at -$185.0 million in Q1 2026, -$122.6 million in Q4 2025, and -$180.4 million in Q3 2025.